National Pharma Audioconferences
|
|
THURSDAY, AUGUST 12, 2010
|
Examining the Latest Developments in Drug and Device CIAs How Corporate Integrity Agreements Continue to Reshape Compliance
|
|
WEDNESDAY, JUNE 16, 2010
|
Ten Emerging Risk Areas for Drug and Device Companies
|
|
TUESDAY, DECEMBER 1, 2009
|
Lessons of Pfizer's $2.3 Billion Off-Label Settlement
|
|
WEDNESDAY, DECEMBER 17, 2008
|
How State Attorneys General Are Reshaping Pharmaceutical Marketing and Compliance through Fraud Investigations and Settlements
Analysis of Eli Lilly's $62 Million Zyprexa Settlement and Pfizer's $895 million Bextra Settlement
A National Audioconference Sponsored by Harvard Health Policy Review and Rx Compliance Report
|
|
TUESDAY, DECEMBER 9, 2008
|
Advanced Implementation Strategies for a Compliant Grant Process
|
|
THURSDAY, DECEMBER 4, 2008
|
The Lessons of Cephalon's $425 Million Off-Label Settlement: A New Model for Off-label Enforcement
|
|
TUESDAY, AUGUST 5, 2008
|
Analyzing the Newly Revised PhRMA Code
|
|
TUESDAY, JUNE 17, 2008
|
Operating in an Uncertain Environment: The Impact of FDA's Draft Guidance on Medical Journal Reprints and Other Recent Developments
|
|
TUESDAY, MAY 27, 2008
|
Dealing with Transparency - How Drug and Device Companies are Operationalizing Disclosure of Educational Grants
|
|
WEDNESDAY, MARCH 26, 2008
|
Lessons from Merck's $671 Million Medicaid Drug Pricing Settlement
|
|
WEDNESDAY, JANUARY 9, 2008
|
Industry-Supported CME under Fire: Mitigating Risk and Enhancing Compliance
|
|
MONDAY, NOVEMBER 26, 2007
|
Lessons of BMS' $515 Million Settlement for Off-label Promotion, Kickbacks and Drug Pricing
|
|
WEDNESDAY, DECEMBER 13, 2006
|
The InterMune Off-label Settlement and the Rise of Deferred Prosecution Agreements
|
|
WEDNESDAY, NOVEMBER 29, 2006
|
How the Democratic Takeover of Congress will Impact Pharma
|
|
WEDNESDAY, MARCH 8, 2006
|
Compliance in a Highly Litigious World - Creating Good Documents and Avoiding Bad Ones
|
|
TUESDAY, DECEMBER 6, 2005
|
Global Compliance Systems: The Next Horizon for Pharma Compliance
|
|
THURSDAY, OCTOBER 27, 2005
|
Understanding the Inner Workings of FDA: - A Conversation With Peter Barton Hutt,"the Unofficial Dean of Washington Food and Drug Lawyers"
|
|
TUESDAY, SEPTEMBER 13, 2005
|
Overview and Implications of PhRMA's DTC Drug Marketing Guidelines
|
|
THURSDAY, JULY 28, 2005
|
Pharmaceutical Drug Pricing and Reporting Issues
|
|
WEDNESDAY, JUNE 8, 2005
|
Fraud and Abuse Issues for Medical Device Companies
|
|
MONDAY, MAY 2, 2005
|
The New California State Law and Other State Laws Targeting Pharmaceutical Sales and Marketing
|
|
MONDAY, APRIL 11, 2005
|
FDA's Final Risk Management Guidance: Improving Drug Safety Through RiskMAPs (Risk Minimization Action Plans)
|
|
TUESDAY, FEBRUARY 17, 2005
|
Update on the Medicare Drug Benefit and Medicare Advantage Regulations
|
|
THURSDAY, OCTOBER 26, 2004
|
The Expanding Scope of Fraud Investigations and Enforcement in Clinical Trials, Publication and Off Label Use
|
|
WEDNESDAY, JUNE 23, 2004
|
Lessons of the Pfizer Settlement for Off Label Promotion - Compliance Issues and Practices
|
|
TUESDAY, MAY 11, 2004
|
The Lessons of the Medco Settlement and Implications for PBM Regulation, Roles and Operations
|
|
TUESDAY, MARCH 23, 2004
|
Analysis of the FDA's Draft Guidance on Direct to Consumer (DTC) Advertising
|
|
TUESDAY, FEBRUARY 10, 2004
|
PBM Regulation, Investigation, Prosecution and Compliance
|
|
WEDNESDAY, JANUARY 28, 2004
|
The New Medicare-Endorsed Prescription Drug Discount Card Program: How it Will Work and Who Will Participate
|
|
WEDNESDAY, JANUARY 14, 2004
|
The Implications of the New Medicare Prescription Drug Legislation for Pharmaceutical Manufacturers, PBMs and Health Plans
|
|
THURSDAY, OCTOBER 16, 2003
|
The New Risk Area - Internal Investigations in a Post Sarbanes Oxley World
|
|
THURSDAY, OCTOBER 2, 2003
|
Off Label Promotion - Compliance Issues and Practices
|
|
THURSDAY, SEPTEMBER 18, 2003
|
Operationalizing the OIG Pharmaceutical Guidance - Grants, Consulting Agreements and Sales and Marketing
|
|
WEDNESDAY, MAY 21, 2003
|
An Analysis of the New OIG Model Compliance Guidance for the Pharmaceutical Industry
|
|
TUESDAY, OCTOBER 22, 2002
|
An Analysis of the New OIG Model Compliance Guidance for the Pharmaceutical Industry
|
|
TUESDAY, OCTOBER 8, 2002
|
The Implications of New Corporate Governance Rules on Compliance in the
Pharmaceutical Industry
|
|
WEDNESDAY, MAY 29, 2002
|
HIPAA for Pharmaceutical Manufacturers, PBMs, and Pharmacies
|
|
